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Summary 
Background 
Buruli ulcer can cause disfigurement and long-term loss-of-function. It is under-diagnosed and 
under-reported, and its current distribution is unclear. We aimed to synthesise and evaluate data on 
BU prevalence and distribution. 
Methods  
We conducted a systematic review of BU prevalence, and used an evidence consensus framework to 
describe and evaluate evidence for BU distribution worldwide. We searched online databases from 
inception to 06/08/2018 for records of BU and M. ulcerans detection, with no limits on study type, 
date, or location. We included population-based surveys presenting BU prevalence estimates in the 
systematic review, extracting prevalence estimates with 95% CIs. We extracted geographical data on 
the occurrence of BU cases and M. ulcerans detection from studies of any type. Occurrence records, 
reports to WHO and the Global Infectious Diseases and Epidemiology Network, and national BU 
surveillance data were included in an evidence consensus framework to grade the strength of 
evidence for BU endemicity. This study is registered with PROSPERO, number CRD42018116260. 
Findings 
2,763 titles met the search criteria.  We extracted prevalence estimates from ten studies and 
occurrence data from 208. Prevalence estimates within study areas ranged from 3.2- 26.9 per 
10,000. There was evidence of BU in 32 countries and consensus on presence in 12.    
Interpretation 
The global distribution of BU is uncertain, and potentially wider than currently recognised. These 
maps represent the strongest available evidence on BU distribution to date, and have many 
potential applications, from directing surveillance activities to informing burden estimates.  
Funding 
The AIM Initiative was the sole funder. 
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Background (343 words) 
Buruli ulcer (BU) is a neglected tropical disease caused by the environmental pathogen 
Mycobacterium ulcerans. It primarily occurs in West and Central Africa, but also in parts of Asia, 
South America, the Western Pacific and Australasia.1,2  It is considered an important public health 
problem due to the characteristic necrotic ulcers it causes, and the scarring and deformity which can 
persist after treatment.3 Although its mode of transmission is not fully understood, contact with 
slow-flowing, stagnant, or disturbed water bodies is an important risk factor.4  
BU was reported in 34 countries from 1960-2015,4 but there is lack of consensus on where 
transmission currently occurs. Ten countries reported a total of 1,864 cases to the WHO in 2016,1 
but this is recognised to reflect a small proportion of the total burden. Cross-sectional surveys within 
endemic countries have demonstrated under-reporting of BU,5-7 for reasons including the chronic, 
stigmatising nature of the disease, its rural distribution, patients’ lack of access to healthcare or 
preference for traditional healers, and lack of awareness or resources within health systems.4,8 
Misdiagnosis may also contribute to under-detection: BU has a range of non-specific presentations 
which can be confused with other skin conditions, especially in the absence of confirmatory tests.9,10  
Therefore, available data does not provide a full or accurate representation of BU burden and 
distribution: essential information for targeting of active case detection, which is a key part of 
control,3 and for directing resources for case management.  
Estimating the global burden and population at risk of BU requires detailed information on the 
geographical limits and prevalence of the disease. We aimed to synthesise available data on BU 
prevalence and occurrence and environmental occurrence of M. ulcerans, including WHO reports, 
national surveillance programmes, the grey literature, and peer-reviewed literature. We undertook a 
systematic review of population-based studies reporting the prevalence of BU, providing a descriptive 
analysis of BU epidemiology within known-endemic areas. We used an evidence consensus 
approach11,12 to delineate the overall distribution of previously reported cases and to quantify the 
strength of evidence for BU presence or absence in every country worldwide.  
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Methods (1266 words) 
This review is registered in the PROSPERO International Prospective Register of systematic reviews; 
CRD42018116260. 
Information sources  
Data sources included peer-reviewed literature, conference proceedings and abstracts and 
government reports (grey literature), data reported to WHO from 2006-2017,1 data reported 
through the GIDEON network,13 and surveillance datasets from national BU programmes in 
Cameroon, Ghana, Nigeria and Togo. Peer-reviewed literature was identified from searches of 
PubMed and Web of Science databases, updated on 06/08/2018. Additional publications were 
identified from reference lists of identified papers.  
Literature Search  
We used the search terms (OR): “Buruli ulcer*”, (“Mycob* AND ulcer*”), “Bairnsdale ulcer”. There 
were no limits on publication date, study type, or location. We included English, French, and Spanish 
language publications. Details in section S.1.1, Supplementary File. 
Eligibility criteria  
Population-based BU surveys were included in the systematic review if they reported the prevalence 
of BU within a defined geographical area, or information allowing this to be calculated.  
Publications were eligible for inclusion in the evidence consensus if they reported geographical 
locations with evidence of M. ulcerans infection in humans or animals, or detection of M. ulcerans in 
animal and environmental samples.  
There were no limits on publication date, participant population, study type or location. Articles that 
did not report original data were excluded.  
Study selection  
Titles were screened to exclude non-relevant publications. Abstracts of selected records were 
screened to identify papers which apparently fulfilled selection criteria. Full texts of selected articles 
were read to identify studies meeting the selection criteria. Studies that recruited patients from 
health facilities or used strains of M. ulcerans isolated from clinical samples were included in the 
evidence consensus framework only if patients’ home addresses were provided. Cases with recorded 
travel history to several endemic regions were excluded. If a dataset was duplicated in numerous 
papers, the most comprehensive was included.  
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Data extraction 
Data from surveillance datasets and selected publications was extracted into a bespoke Microsoft 
Excel spreadsheet used for the Global Atlas of Helminth Infections.14 The original spreadsheet was 
piloted on a subset of studies, and then developed. Authors were contacted for additional data if 
community-level results were not presented. The data extraction was performed by a single author 
and checked by a second one. Data extracted included: i) the number or prevalence of cases, ii) the 
sample size and survey coverage (for population-based studies) iii) the case detection method 
(survey, case search, passive detection), iv) the recording date, v) the diagnostic procedure, including 
any confirmatory tests (polymerase chain reaction (PCR) for M. ulcerans gene targets; Ziehl Neelsen 
(ZN) staining; culture for M. ulcerans; histopathological analysis) and their results, and vi) the 
location of origin (patient residence or endemic area visited if the case originated from a non-
endemic area). Areas described as ‘endemic’, with no information on case detection, were not 
included.  
Data extracted on environmental detection of M. ulcerans included: i) sample date and location, ii) 
sample type (water, soil, plant, animal- clinical, animal- faeces), iii) taxonomic details for animal 
samples, iv) confirmatory tests, and v) numbers of samples tested and positive. 
Geographic coordinates of occurrence locations were extracted if were provided in the publication. 
Otherwise, point locations were georeferenced remotely (section S.1.2, Supplementary File). Point 
locations that could not be georeferenced were linked to the lowest administrative level provided in 
the publication. Polygon areas corresponding to first and second administrative divisions were linked 
to units defined in the Database of Global Administrative Areas.15 
Summary measures  
The principal summary measure for the systematic review was BU prevalence. The quality of 
prevalence studies was assessed using a framework based on the Newcastle-Ottawa score,16  
adapted from a systematic review of podoconiosis prevalence17 (S.3. Supplementary File). This took 
account of the sampling frame, response rate, diagnostic specificity, and statistical analysis. The risk 
of outcome bias was assessed according to whether sampling was done at random or using 
convenience sampling within the study area. The number of studies from each country, relative to 
the number of cases reported to WHO, was used as an indicator of geographical bias between 
studies.  
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The outcome measures for the evidence consensus framework were BU and M. ulcerans occurrence. 
Occurrence locations were assigned local- and national-level quality scores reflecting 
contemporariness and specificity (S.1.3- S.1.4, Supplementary File). We used the number of studies 
included in the evidence consensus framework, and the number reporting laboratory confirmation, 
as indicators of geographical bias in reporting and study quality. 
Data Synthesis 
We extracted prevalence estimates from included surveys and calculated 95% confidence intervals 
(CIs) using Byar’s method.18 
Occurrence data was synthesised through an evidence consensus approach using a weighted scoring 
system, following that used to determine the global distribution of other diseases.11,12 Separate 
frameworks were used to assess the evidence for BU presence or absence at national level (Figure 
1), evidence for BU presence at sub-national level (Figure 2), and evidence for environmental 
occurrence of M. ulcerans at sub-national level (section S.1.5, Supplementary File).  
National level 
The major features for the national evidence framework were: 
- Health reporting organisations: Countries were assigned a score based on recent and historical 
reporting to WHO and reports through GIDEON. 
- Occurrence data quality: Each country was assigned the highest data quality score of occurrence 
records within it.  
- Number of cases: The number of cases reported at each location was weighted by the local-level 
data quality score, and the weighted totals were aggregated to national level.  
- Evidence for absence: In countries with no cases reported, the consensus score was designed to 
quantify the evidence for BU absence, reflecting the possibility of under-reporting due to (i) 
weak surveillance capacity, or (ii) misdiagnosis as known endemic diseases with similar 
presentations19 (confounding diseases)  (Figure 1B). As a proxy for surveillance and diagnostic 
capacity, health expenditure (HE) reported by WHO20 was categorised as low (<$100), medium 
($100≤HE<$500) or high (HE≥$500), following the approach of previous authors and supported 
by evidence that higher HE is associated with better health system performance21. 
 
The confounding diseases with available evidence on their global distribution were: cutaneous 
leishmaniasis (CL),12,22 leprosy,23 lymphatic filariasis (LF),14 onchocerciasis,24 tropical ulcer (TU)2 
and yaws25. Estimates of the frequencies of the common presentations of these diseases and BU 
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were obtained from literature review and expert opinion.24,26-29 For each confounding disease, 
the frequency of each presentation shared with BU was multiplied by the frequency of the 
presentation among BU cases, and the products summed to generate a symptom overlap score 
(Table S1, Supplementary File).  
 
For each country, the symptom overlap scores for its endemic confounding diseases were 
summed, then down-weighted if HE was high or medium. This score was added to an ordinal HE 
score reflecting likelihood of under-detection/ non-reporting.   
Figure 1 approximately here
 
Sub-national level 
Each upper administrative level was assigned the highest local-level evidence quality score of the 
occurrence records which fell within it or within 5km distance of its boundaries, and a score 
reflecting total number of cases within the unit (Figure 2).  
 
Figure 2 approximately here
 
Environmental occurrence of M. ulcerans 
Environmental detection records were assigned to the upper administrative unit15 they fell within. 
Each unit was assigned the highest evidence quality score of records within it, and a score reflecting 
the total number of detection records within it, weighted by evidence quality score (Table S2, 
Supplementary File).  
Role of the funding source  
The AIM Initiative was the sole funder of this work. The AIM Initiative facilitated connections with 
disease control programmes for data transfer, but had no input in the systematic review or decision 
to publish. Hope Simpson had full access to all data in the study and final responsibility for the 
decision to submit for publication. 
Kebede Deribe is supported by the Wellcome Trust [grant number 201900] as part of his 
International Intermediate Fellowship. The Wellcome Trust has not played any role in the design, 
conduct, analysis, or writing up of the study.  
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Results (918 words) 
Study selection 
The literature search identified 2,849 records after de-duplication (Figure 3). Another 86 were 
identified through other sources. The most common reason for exclusion was lack of information on 
patient origin. Full text was unavailable for 46 studies. Ten BU prevalence surveys were included in 
the systematic review.7,8,30-35 Occurrence data was extracted from 208 publications and five 
surveillance datasets. 
 
Figure 3 approximately here 
 
Study characteristics  
Three surveys conducted in Cameroon, two in each of Benin, Cote d’Ivoire and Ghana, and one in 
the DRC (Table 1) were included. The largest was a national survey in Cote d’Ivoire, covering an 
estimated 14,500,000 people.5 
 
Seven surveys provided explicit details on the sampling frame. All surveys were community-based 
and aimed to reach the entire population of chosen communities. Seven covered the entire study 
area, one surveyed randomly selected communities within the study area, one surveyed a 
convenience sample of communities and one used random and convenience sampling. Only one 
reported the survey coverage.8 Five reported laboratory confirmation of all or a subset of cases, five 
used clinical case definitions. Only one study reported prevalence with 95% CIs.8  
Overall prevalence estimates within the study area ranged from 3.2- 26.9 cases per 10,000. The 
highest reported community prevalence of BU was 2,200 per 10,000.34
 
Table 1 approximately here 
 
Evidence consensus  
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Human cases were recorded from 32 countries, and inferred from two further countries from which 
strains were reported to have been isolated (Iran and Malaysia) 36,37. Most cases (94·9%) were from 
the African (AFRO) region, 5·6% were from the West Pacific (WPRO) region, and less than 1% were 
from other WHO regions. Evidence of M. ulcerans in environmental and animal samples was 
reported from nine countries. A summary of data extracted from all publications is provided in Table 
S.3 of Supplementary File. 
Cases were recorded from 1952- 2017, with the greatest number detected in 1999 (3,401). From 
1952- 1998, between zero and five countries each year had evidence of BU based on peer-reviewed 
literature. The disease was identified in nine countries in 1999. Including data reported to WHO, 
available from 2002, between twelve and eighteen countries each year had evidence of BU. 
Laboratory confirmation of at least one case was reported by 71% of studies included, and 62.5% 
used PCR. However, most occurrence records (77%) were categorised as clinically diagnosed only, 
because laboratory results were not disaggregated by unique locations. 
Symptom overlap scores for the confounding diseases are shown in Table 2. TU had the highest 
score, reflecting the high frequency of ulcers among BU and TU.2,35 BU was considered less likely to 
be misdiagnosed as CL or yaws, which present a lower frequency of ulcerous forms.26,27 
Onchocerciasis, leprosy and LF had symptom overlap scores below 6%. 
Full results of the evidence consensus framework are provided at country level in Supplementary 
File, Table S.5. 
 
Table 2 approximately here 
 
We identified consensus on BU presence in twelve countries, which collectively reported 34,890 
cases to WHO from 2002- 2016 (96·2% of all cases reported to WHO in this period). Australia and 
Japan were the only non-African countries with consensus on presence (Figure 4).  
The African countries with evidence of BU were mostly clustered in a block covering much of Central 
and West Africa. Countries around this block generally had weaker evidence for absence, with a 
higher number of endemic confounding diseases and lower HE. In the AMRO region, evidence of BU 
was strong in French Guiana and Peru, and moderate in Brazil, Mexico and Suriname. Despite strong 
evidence of BU cases from French Guiana in literature reports, the disease has never been reported 
10 
 
to WHO, so full consensus on endemicity was not reached through the framework. There was 
moderate evidence for BU in China. Endemicity status was indeterminate in Burkina Faso, Ethiopia, 
Honduras, Indonesia, Malawi, Malaysia and Suriname. Niger, Eritrea, the Gambia, and Mauritania, all 
in the AFRO region, had the weakest evidence for absence, being endemic for CL and TU, and having 
low health expenditure. Fourteen other countries- of which 12 were in Africa- had weak evidence for 
absence.   
Figure 4 approximately here 
 
Sub-national areas with evidence for endemicity were mostly clustered within equatorial, humid 
tropical and tropical climate zones of West and Central Africa (Figure 5). Areas with evidence for BU 
in Eastern, Southern, and non-coastal Central Africa, and other parts of the world, were more 
isolated (Figures 5 and 6).  
 
Figure 5 approximately here 
Figure 6 approximately here 
 
Buruli ulcer in animals and M. ulcerans in the environment 
The areas with evidence of M. ulcerans in animal and environmental samples are shown in Figure 7. 
BU disease was reported in wild and domestic animals in Australia, Benin, Cameroon and Ghana, and 
M. ulcerans DNA has been detected in faecal samples from animals in Australia (details and 
references in Table S.4). DNA from mycolactone-producing environmental bacteria has been 
identified in biotic and abiotic samples from waterbodies in eight BU endemic countries, and the 
United States of America (details and references in Table S.4). However, it is not clear if the 
American strains would be capable of causing BU disease in humans.  
 
Figure 7 approximately here 
 
 
Discussion (1011 words) 
We have collated available on BU prevalence and occurrence, and evidence of M. ulcerans in animals 
and the environment. The evidence consensus framework applied has allowed us to expand on 
existing maps of BU distribution 2,38 in several ways. The maps presented include evidence from a 
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wider range of sources, provide finer resolution, and quantify the strength of evidence for BU 
presence, as well as absence in countries where BU has not been reported.  
There have been few BU prevalence surveys, and most of those identified did not report detailed 
statistical analysis or indicators such as coverage. We did not undertake a meta-analysis because 
of the heterogeneous nature of compiled studies. Furthermore, most studies included were 
conducted in areas assumed to have a high rate of BU, so a summary prevalence would tend to 
overestimate the disease burden in the overall population. 
Prevalence estimates reported by population-based studies were high relative to incidence data 
reported through WHO. This is likely to reflect underreporting of BU through routine systems, but 
the studies included may have overestimated BU prevalence due to sampling bias. Two of the ten 
studies included7,35 used convenience sampling as part of the study design, which implies a risk of 
bias in the estimated prevalence. Five studies reported clinical diagnosis according to WHO 
guidelines and five used laboratory confirmation to confirm all or a subset of cases. There was 
geographical bias across the studies included, representing only five countries out of the 32 
identified as having evidence for BU.  
Our investigation identified consensus on BU presence in eight of the ten countries accounting for 
97% of BU cases reported to WHO from 2007- 2016. However, the maps presented demonstrate 
significant remaining uncertainty on the global distribution of BU. There was indeterminate or 
moderate quality evidence of BU in fifteen countries that had not reported data to WHO from 2007- 
2016.  
The national and sub-national evidence consensus maps demonstrate large contiguous areas of 
potential endemicity, both within and between countries, particularly in Central and Western Africa. 
Evidence for BU presence was generally strongest in these contiguous areas. This is likely to be partly 
due to environmental similarity in terms of suitability, and partly due to increased emphasis on case 
detection in areas established as endemic.  
The area of BU presence defined by the sub-national map of BU distribution in Africa (Figure 5) was 
more restricted than that defined by the map of national-level endemicity (Figure 4). This reflects 
the focal and restricted distribution of BU,39 and the lower availability of data at subnational level: in 
some countries, the only available data was that reported to WHO, with no information on sub-
national distribution. Given the recognised scale of BU under-reporting, it is likely that this map 
underestimates the scale of BU distribution. 
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Countries which had not reported BU cases, but were close to those that had, generally had weaker 
evidence for absence than countries located further from areas of BU endemicity. This trend was 
apparent in Africa, South America, and the South East Asia and Western Pacific regions, and reflects 
spatial clustering of countries with lower health expenditure and numerous co-endemic tropical 
diseases, irrespective of their evidence for BU. The proximity of BU-endemic countries to those with 
lowest evidence for BU absence adds further weight to the possibility that BU may occur undetected 
in the latter group, due to cross-border transmission and environmental similarity of neighbouring 
countries.  
Limitations 
While the maps provide finer detail on the distribution of BU than current official maps, they still 
mask the underlying epidemiology of BU. Areas identified as endemic may in fact contain only a few 
localised cases of BU, and be mostly unsuitable for the disease. Due to the focal nature of BU,39 
point-level data on disease occurrence is needed to support investigation into its spatial 
epidemiology. It is hoped that the maps and assembled geographic dataset will support such 
research in the future.  
Studies on M. ulcerans environmental occurrence were limited, and many did not apply sufficiently 
specific tests to differentiate M. ulcerans from other environmental mycobacteria. Therefore, the 
maps of evidence for environmental occurrence of M. ulcerans do not provide a complete 
representation of environmental suitability for the bacterium. Although we assigned the maximum 
possible evidence quality score to clinical cases confirmed by PCR and environmental occurrences 
confirmed by q-PCR, these tests still entail a risk of false positives, as demonstrated by an external 
quality assessment including several reference laboratories which performed confirmatory testing in 
studies we included.40  
There was marked geographical bias in the occurrence records, reflecting different levels of research 
and surveillance activity between countries. Further analysis of the data underlying this work should 
account for this bias. In the context of this study, this bias is expected to have impacted areas where 
there were few studies, but not where there were many studies, since additional studies would not 
change the outcome measure unless they provided higher quality data.  
Implications 
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The areas with highest consensus for presence are presumably most suitable for BU transmission, 
and would be targets for surveillance and research since they represent known disease foci. Some 
countries with strong evidence for BU are not shown in the current WHO map of BU,38 
demonstrating that the disease is more widely distributed than the official map suggests. This has 
important implications for understanding and communicating the global burden of BU. We have also 
expanded upon the WHO map of BU by qualitatively grading the strength of evidence for 
endemicity. In doing so we have identified numerous countries with moderate or indeterminate 
evidence of BU, and those with weakest evidence for its absence, which may require further 
investigation to clarify the global distribution of BU. Active case finding in areas which have 
previously reported BU, and close to those currently reporting, should be prioritised. The assembled 
point-level dataset represents a novel resource for continent-wide exploration of environmental and 
biological predictors of BU, and estimation of the global burden and population at risk. The 
information provided by investigations such as these will help to target future control efforts and 
evaluate their impact. 
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Figure titles and legends 
Figure 1: Evidence consensus framework used to assess strength of evidence for BU presence and 
absence at national level  
 
Part A used for all countries, part B additionally for countries with no evidence of reported cases. Numbers in 
bold show each constituent’s maximum score. 
*Score was adjusted post-hoc for countries from which M. ulcerans strains had been isolated, if no cases 
meeting inclusion criteria were identified.  
PCR = polymerase chain reaction. ZN = Ziehl Neelsen staining. 
 
Figure 2: Evidence consensus framework used to assess strength of evidence for BU presence at 
sub-national level  
 
Numbers in bold show each constituent’s maximum score. 
 
Figure 3: Selection of eligible studies 
 
Figure 4: Evidence consensus for BU presence and absence worldwide 
 
Figure 5: Evidence for Buruli Ulcer Endemicity at National and Upper Sub-National Levels in in 
Africa 
 
Figure 6: Evidence for Buruli Ulcer Endemicity at National and Upper Sub-National Levels in Central 
and South America and the Pacific Region. 
 
Figure 7: Evidence for Environmental Occurrence of Mycobacterium ulcerans at Upper Sub-
National Level and for Buruli ulcer endemicity at national level in West and Central Africa, the 
Western Pacific Region, and South America
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Table 1: Characteristics of population-based BU prevalence surveys included in the systematic review 
Main author, 
year published Country 
Year of 
survey Location Study design Case ascertainment 
N. active 
cases 
Sample 
size Prevalence (95% CI) 
Quality 
score  
Johnson et al., 
200541 Benin 2004 Lalo commune 
Exhaustive preparatory phase 
followed by validation of 
suspected cases 
Clinical diagnosis following 
WHO guidelines 160 86,819 18.4 (15.7- 21.5) 4 
Sopoh et al., 
201031 Benin 2006 Zè district 
Exhaustive preparatory phase 
followed by validation of 
suspected cases 
Clinical diagnosis following 
WHO guidelines 222 82,450 26.9 (23.5- 30.7) 4 
Noeske et al., 
20047 Cameroon 2001 
Ayos and 
Akonolinga 
health districts 
Exhaustive survey in 
convenience sample of 
communities with suspect cases 
Clinical diagnosis, a subset 
confirmed by PCR and/or ZN 
staining 
202 98,500 20.5 (17.8- 23.5) 2 
Porten et al., 
20098 Cameroon 2007 
Akonolinga 
district 
Exhaustive survey in a random 
selection of communities 
Clinical diagnosis following 
WHO guidelines, active and 
total cases reported separately 
56 26,679 21.0 (15.9- 27.3) 5 
Bratschi, 201342  Cameroon 2010 Bankim Health District 
Exhaustive survey of health 
district 
Clinical diagnosis, a subset 
confirmed by PCR 25 48,962 5.1 (3.3- 7.5) 3 
Kanga 200143 Côte d'Ivoire 1995 Cote d’Ivoire 
Exhaustive survey of entire 
country 
Suspect cases identified by 
CHWs, confirmed by clinicians 4,642 14,500,000 3.2 (3.1- 3.3) 2 
Ecra et al., 
200532 
Côte 
d'Ivoire 1998 
Zoukoougbeu 
sub-prefecture 
Exhaustive survey of entire sub-
prefecture 
Nodules detected clinically, M. 
ulcerans confirmed by 
histopathological analysis 
54 47,742 11.3 (8.5- 14.8) 3 
Mavinga Phanzu 
et al., 2013 33 DRC 2008 
Kimpese and 
Nsona-Mpangu 
Rural Health 
Zones 
Exhaustive preparatory phase 
followed by validation of 
suspected cases 
Clinical diagnosis following 
WHO guidelines, a subset 
confirmed by PCR 
259 237,418 10.9 (9.6- 12.3) 6 
Amofah et al., 
199334 Ghana 1991 
Amansie West 
district 
Exhaustive survey of entire 
district 
Clinical diagnosis, a subset 
confirmed by ZN staining 90 130,000 6.9 (5.6- 8.5) 4 
Ampah et al., 
201635 Ghana 2013 Offin river valley 
Exhaustive survey in random 
sample (n=10) and convenience 
sample (n=3) of communities 
within 5km of the Offin River  
Clinical diagnosis in following 
WHO guidelines, a subset 
confirmed by PCR 
7 20,390 3.4 (1.4- 7.1) 6 
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PCR = polymerase chain reaction. ZN = Ziehl Neelsen staining. DRC = Democratic Republic of Congo. 1Prevalence of nodules only- did not include other 
forms of BU
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Table 2: Symptom overlap scores (0- 100) for diseases whose symptoms can also be caused by BU. 
Confounding disease Summed score 
Tropical Ulcer 70.9 
Cutaneous leishmaniasis 35.0 
Yaws 16.3 
Onchocerciasis 5.7 
Leprosy 3.6 
Lymphatic filariasis  0.5 
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Figure 1: Evidence consensus framework used to assess strength of evidence for BU presence and absence at national level
 
Part A used for all countries, part B additionally for countries with no evidence of reported cases. Numbers in bold show each constituent’s maximum score. 
ZN = Ziehl Neelsen,   
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Figure 2: Evidence consensus framework used to assess strength of evidence for BU presence at sub-national level  
 
Numbers in bold show each constituent’s maximum score.  
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Figure 3 Selection of eligible studies 
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Figure 4: Evidence consensus for BU presence and absence worldwide 
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Figure 5. Evidence for Buruli Ulcer Endemicity at Upper Sub-National Level in Africa 
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Figure 6. Evidence for Buruli Ulcer Endemicity at National and Upper Sub-National Levels in Central and South America and the Pacific Region.
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Figure 7. Evidence for Environmental suitability for Mycobacterium ulcerans at Upper Sub-National Level and for Buruli ulcer endemicity at upper sub-
national level in West and Central Africa, the Western Pacific Region, and the Americas 
 
  
